Last year Canada garnered global headlines when it made an historic shift to a federally legal, commercial medical cannabis industry. In the rush to establish new companies, produce consistent supply of quality products, and develop relationships with physicians and patients, the industry has failed to clearly articulate a common code of ethics.
Greg Engel, a pharmaceutical executive with a history of leading early-stage companies to new levels of growth, is Chief Executive Officer at Tilray, a Health Canada licensed producer and a national leader in the production and distribution of premium medical cannabis. At Tilray, Greg leads a growing team of industry-leading experts working to advance the science, safety, and efficacy of medical cannabis for patients and physicians in Canada and around the world.
I have dedicated my entire career to the health care industry because it's important to me to spend my life doing something that helps people. Now, after more than 25 years, I have decided to leave behind the big pharma establishment in order to embark on a new journey on the cutting edge of health care, as the first CEO of Tilray, Canada's leading licensed producer of medical cannabis. Here are the top five reasons why: Patients deserve better. Last year, Canada made history when it became one of the first countries in the world to create a federally-sanctioned, commercial medical cannabis industry that treats medical cannabis more like medicine than contraband.
03/10/2015 05:27 EDT
SUBSCRIBE AND FOLLOW
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements. Learn more